ABP-160

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameABP-160

Drug Alias NameABP-160

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionProgrammed death-ligand 1 blockersCluster of differentiation 47 inhibitors

TargetsProgrammed death-ligand 1Cluster of differentiation 47

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbpro Corp

China Registration ClassN/A

Develop Information

Active CompaniesAbpro Corp

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A